GlobeNewsWire
03 Sept 2026, 10:50 UTC · 11w ago
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
Impact · against what's priced in
The positive Phase 3 subgroup data for deucrictibant IR capsules reduces regulatory risk by demonstrating consistent efficacy across key geographic markets. While the translational and proteomic data provide scientific validation, the clinical consistency in North America and Europe is the primary driver of value.
- PHVS+0.60
No priced-in read yet





